Table 3.
Patient characteristics.
| Group 1 6 | Group 2 | Group 3 | p value | |
|---|---|---|---|---|
| Post-operative Gleason score ≤ | Post-operative Gleason score 7 (3 + 4) | Post-operative Gleason score 7 (4 + 3) and over | ||
| Mean ± Standard Deviation | ||||
| No. | n = 25 | n = 71 | n = 66 | |
| Age (years) | 65.72 ± 6.07 | 66.45 ± 5.82 | 68.70 ± 5.07 | 0.022a |
| NPFV (cm3) | 1.84 ± 0.76 | 2.45 ± 1.13 | 2.8 ± 1.56 | 0.001a |
| AFA (cm2) | 137.51 ± 65.12 | 126.12 ± 50.75 | 144.42 ± 61.27 | 0.177a |
| SFT (cm) | 3.84 ± 1.56 | 3.7 ± 1.18 | 3.8 ± 1.34 | 0.853a |
| BMI (kg/m2) | 27.87 ± 4.69 | 27.31 ± 3.61 | 27.73 ± 4.28 | 0.781a |
| Initial PSA (ng/ml) | 9.86 ± 5.29 | 11.06 ± 5.71 | 15.21 ± 11.11 | 0.006b |
| PV (cm3) | 63.29 ± 26.99 | 54.71 ± 32.07 | 51.01 ± 19.94 | 0.051b |
| WHO classification N (%)* | ||||
| No. | n = 23 | n = 69 | n = 64 | 0.946c |
| Normal weight | 7 (30.4) | 22 (31.9) | 18 (28.1) | |
| Overweight | 9 (39.1) | 31 (44.9) | 30 (46.9) | |
| Obesity | 7 (30.4) | 16 (23.2) | 16 (25) | |
| Pathological stage N (%)* | ||||
| No. | n = 25 | n = 71 | n = 66 | 0.001c |
| T2 | 20 (80) | 43 (60.6) | 25 (37.9) | |
| T3 | 5 (20) | 28 (39.4) | 41 (62.1) | |
| D’Amico risk classification N (%)* | ||||
| No. | n = 25 | n = 71 | n = 66 | <0.001c |
| Low | 18 (72) | 18 (25.4) | 2 (3) | |
| Intermediate | 6 (24) | 40 (56.3) | 27 (40.9) | |
| High | 1 (4) | 13 (18.3) | 37 (56.1) | |
NPFV = Normalised periprostatic fat volume; AFA = Abdominal fat area; SFT = Subcutaneous fat thickness; BMI = Body mass index; PSA = Prostate specific antigen; PV = Prostate volume.
Patients were stratified according to post-operative Gleason score.
aANOVA, bKruskal-Wallis test, c χ 2 test.
*(%) within each group.
P value is significant <0.05.